/ADTX
ADTX Stock - Aditxt, Inc.
Healthcare|BiotechnologyNASDAQ
$1.17-7.54%
$0.10 (-7.54%) • Dec 19
59
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.68
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+13633.9%upside
Target: $160.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ADTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.15 – $1.18
TARGET (TP)$160.00
STOP LOSS$1.07
RISK/REWARD1:1671.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.29
52W High$6808.25
52W Low$1.13
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $133,985 | $645,176 | $933,715 | $105,034 | N/A |
| Gross Profit | $-493,000 | $-111,660 | $166,936 | $27,055 | $-17,773 |
| Gross Margin | -368.0% | -17.3% | 17.9% | 25.8% | N/A |
| Operating Income | $-27,864,000 | $-26,062,425 | $-25,480,000 | $-41,935,000 | $-8,872,209 |
| Net Income | $-34,446,000 | $-32,380,839 | $-27,650,000 | $-46,371,000 | $-9,149,227 |
| Net Margin | -25708.8% | -5018.9% | -2961.3% | -44148.6% | N/A |
| EPS | $-346053.00 | $-249623.74 | $-14.89 | $-2.43 | $-1.33 |
Company Overview
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ADTXBeat Rate
19%
Last 16 quarters
Avg Surprise
-3210645.4%
EPS vs Estimate
Beats / Misses
3/13
Last 12 quarters
Latest EPS
$-73.15
Q4 2025
EPS Surprise History
Q2 24
-23.5%
$-36.82vs$-29.81
Q2 24
-174.5%
$-91400.00vs$-33300.00
Q3 24
-55.8%
$-41900.00vs$-26900.00
Q4 24
-1.3%
$-27767.50vs$-27400.00
Q1 25
+99.6%
$-100.71vs$-26400.00
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q4 2025 | Nov 17, 2025 | — | $-73.15 | — | — |
Q3 2025 | Aug 14, 2025 | — | $-392.05 | — | — |
Q2 2025 | May 15, 2025 | — | $-8.12 | — | — |
Q1 2025 | Mar 24, 2025 | $-26400.00 | $-100.71 | +99.6% | ✓ BEAT |
Q4 2024 | Nov 18, 2024 | $-27400.00 | $-27767.50 | -1.3% | ✗ MISS |
Q3 2024 | Aug 19, 2024 | $-26900.00 | $-41900.00 | -55.8% | ✗ MISS |
Q2 2024 | May 20, 2024 | $-33300.00 | $-91400.00 | -174.5% | ✗ MISS |
Q2 2024 | Apr 2, 2024 | $-29.81 | $-36.82 | -23.5% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-59900.00 | $-487699.97 | -714.2% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-1156000.00 | $-367999.97 | +68.2% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-2.78 | $-1.31 | +52.9% | ✓ BEAT |
Q2 2023 | Apr 17, 2023 | $-1.48 | $-760241.85 | -51367592.6% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-999999.94 | $-2107999.75 | -110.8% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $5.50 | $-6.50 | -218.2% | ✗ MISS |
Q2 2022 | May 16, 2022 | $5.50 | $-7.00 | -227.3% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $11.50 | $-15.50 | -234.8% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $8.50 | $-20.00 | -335.3% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-2.50 | $-21.00 | -740.0% | ✗ MISS |
Q2 2021 | May 12, 2021 | $-10.50 | $-23.00 | -119.0% | ✗ MISS |
Latest News
Aditxt shares are trading lower after the company announced a $20 million offering.
📉 NegativeBenzinga•Dec 15, 2025, 03:27 PM
Aditxt Increases At-The-Market Stock Offering Cap To $20M
➖ NeutralBenzinga•Dec 12, 2025, 10:36 PM
Aditxt Shares Resume
➖ NeutralBenzinga•Nov 28, 2025, 02:59 PM
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Nov 3, 2025, 01:55 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Oct 31, 2025, 11:50 PM
Aditxt shares are trading lower after the company announced a 1-for-113 reverse stock split effective November 3.
📉 NegativeBenzinga•Oct 30, 2025, 01:10 PM
Aditxt shares are trading lower after the company announced a 1-for-113 reverse stock split effective November 3.
📉 NegativeBenzinga•Oct 29, 2025, 08:37 PM
Aditxt announces 1-for-113 reverse stock split
📉 NegativeSeeking Alpha•Oct 29, 2025, 08:37 PM
Aditxt Announces 1-for-113 Reverse Stock Split Effective Nov. 3
📉 NegativeBenzinga•Oct 29, 2025, 08:32 PM
Aditxt's Pearsanta Begins Enrollment In Clinical Study Evaluating Mitomic Endometriosis Test, Blood-Based Diagnostic Designed To Aid In Early Detection Of Endometriosis
📈 PositiveBenzinga•Oct 27, 2025, 12:41 PM
Evofem Biosciences Sets September 26 Special Meeting For Expected Approval Of Merger With Aditxt
📈 PositiveBenzinga•Sep 9, 2025, 01:29 PM•Also:
Aditxt Plans FDA Submission For First-in-Human Trials In Type 1 Diabetes And Stiff Person Syndrome In Early 2026
📈 PositiveBenzinga•Aug 25, 2025, 01:18 PM
Frequently Asked Questions about ADTX
What is ADTX's current stock price?
Aditxt, Inc. (ADTX) is currently trading at $1.17 per share. The stock has moved -7.54% today.
What is the analyst price target for ADTX?
The average analyst price target for ADTX is $160.00, based on 1 analyst.
What sector is Aditxt, Inc. in?
Aditxt, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ADTX's market cap?
Aditxt, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does ADTX pay dividends?
No, Aditxt, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAIMD
Ainos, Inc.
$2.11
Mkt Cap: $0.0B
ANL
Adlai Nortye Ltd.
$1.52
Mkt Cap: $0.0B
APLM
Apollomics, Inc.
$16.73
Mkt Cap: $0.0B
ATHA
Athira Pharma, Inc.
$6.97
Mkt Cap: $0.0B
BLRX
BioLineRx Ltd.
$3.04
Mkt Cap: $0.0B
CTXR
Citius Pharmaceuticals, Inc.
$1.07
Mkt Cap: $0.0B
GOVX
GeoVax Labs, Inc.
$0.16
Mkt Cap: $0.0B
ICU
SeaStar Medical Holding Corporation
$0.24
Mkt Cap: $0.0B
MBRX
Moleculin Biotech, Inc.
$3.90
Mkt Cap: $0.0B
THAR
Tharimmune, Inc.
$2.32
Mkt Cap: $0.1B
Explore stocks similar to ADTX for comparison